|
Claryfying the photo-toxicity of NDEA and colleagues: the link for elucidation of the skin cancers pathogenesis
|
|
0
|
99
|
April 6, 2024
|
|
Nitrosamine Impurity Test Market expected to grow exponentially by 2029
|
|
0
|
395
|
November 19, 2023
|
|
Controversial but Public Report
|
|
4
|
438
|
April 6, 2024
|
|
Theoretical estimation of the conversion of a tertiary amine to nitrosamine
|
|
8
|
735
|
April 6, 2024
|
|
👨💻 Quantitation of MNP & CPNP in Rifampin and Rifapentine by LC-MS/MS
|
|
0
|
215
|
April 5, 2024
|
|
📅 Ascorbic Acid And Alpha-Tocopherol As Nitrite Scavengers - An Elegant And Simple Solution To Mitigate Nitrosamines In Drug Products -Event
|
|
0
|
479
|
April 5, 2024
|
|
Overlapping gene/mutation patterns between changes induced in p53 and RAS oncogenes by some nitrosamines with those induced within photocarcinogenesis: a good start to unravel the puzzle?
|
|
2
|
95
|
April 5, 2024
|
|
Request for risk assessment and confirmatory testing for nortriptyline containing products
|
|
4
|
381
|
April 3, 2024
|
|
AI Limit for Nitroso Nebivolol
|
|
11
|
1890
|
April 3, 2024
|
|
EMA - Update Appendix 3: Enhanced Ames Test conditions for N-nitrosamines
|
|
8
|
800
|
April 2, 2024
|
|
Sitagliptin NTTP nitrosamine impurity maximum active intake level 37ng to 246.7 ng/per day
|
|
26
|
3316
|
April 2, 2024
|
|
🖩 CPCA Calculation Tool (excel-based) -Updated
|
|
82
|
7721
|
April 1, 2024
|
|
1st release of Lhasa 'Complex Nitrosamines' data sharing initiative
|
|
6
|
902
|
March 31, 2024
|
|
Risk Assessment Study of Nitrosamines for the API Temozolomide Industrial Process -Pub
|
|
1
|
649
|
February 6, 2024
|
|
Antioxidant as a risk mitigation strategy
|
|
5
|
379
|
March 28, 2024
|
|
Acceptable Intakes (AIs) for 11 Small molecule N-nitrosamines (NAs) -Pub
|
|
17
|
1953
|
March 28, 2024
|
|
🇨🇦 Health Canada updated the guidance and Appendix 1(March 15, 2024)
|
|
10
|
1396
|
March 27, 2024
|
|
Chemistry of N-Nitroso Ivacaftor
|
|
5
|
616
|
March 25, 2024
|
|
AI difference between FDA and EMA, HC and TGA
|
|
0
|
528
|
March 22, 2024
|
|
N-Nitrosamine impurity of heterocyclic aromatic ring
|
|
16
|
2535
|
March 22, 2024
|
|
IVACAFTOR (N-Nitroso Ivacaftor)
|
|
0
|
228
|
March 22, 2024
|
|
Nitrosamines in Bacon: a Case Study of Balancing Risks
|
|
1
|
202
|
March 20, 2024
|
|
Nitroso amines quantification in drugs which are having MDD Value more than 10.0g/Day
|
|
2
|
237
|
March 20, 2024
|
|
Calculating Nitrosamine Limits (MasterClass)
|
|
4
|
1625
|
March 19, 2024
|
|
N-nitroso cyclamate
|
|
9
|
356
|
March 15, 2024
|
|
Application of duplex sequencing to evaluate mutagenicity -Pub
|
|
1
|
200
|
March 14, 2024
|
|
🇪🇺 EDQM - top 10 deficiencies observed in new CEP applications
|
|
0
|
462
|
March 14, 2024
|
|
Lack of effect of antioxidants on Biopharmaceutics Classification System (BCS) Class III drug permeability -Pub
|
|
1
|
311
|
March 13, 2024
|
|
NDMA evaluation in battery of in vivo Genotoxicity assays once again leading to AI much greater than 96 ng/day
|
|
0
|
168
|
March 13, 2024
|
|
USP User Forum in 🇨🇦 Toronto
|
|
0
|
127
|
March 12, 2024
|